Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.

Raghavan P, Tumati V, Yu L, Chan N, Tomimatsu N, Burma S, Bristow RG, Saha D.

Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):e507-14. doi: 10.1016/j.ijrobp.2012.05.035. Epub 2012 Jul 12.

2.

Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data.

Ohri N, Dicker AP, Lawrence YR.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):385-93. doi: 10.1016/j.ijrobp.2011.06.1990. Epub 2012 Jan 19. Review.

3.

Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways.

Morgan MA, Lawrence TS.

Clin Cancer Res. 2015 Jul 1;21(13):2898-904. doi: 10.1158/1078-0432.CCR-13-3229. Review.

4.

Radiation-induced signaling pathways that promote cancer cell survival (review).

Hein AL, Ouellette MM, Yan Y.

Int J Oncol. 2014 Nov;45(5):1813-9. doi: 10.3892/ijo.2014.2614. Epub 2014 Aug 20. Review.

5.

Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer.

Willers H, Azzoli CG, Santivasi WL, Xia F.

Cancer J. 2013 May-Jun;19(3):200-7. doi: 10.1097/PPO.0b013e318292e4e3. Review.

6.

Notch inhibitor: a promising carcinoma radiosensitizer.

Yu SD, Liu FY, Wang QR.

Asian Pac J Cancer Prev. 2012;13(11):5345-51. Review.

7.

Cellular and molecular mechanisms underlying oxygen-dependent radiosensitivity.

Liu C, Lin Q, Yun Z.

Radiat Res. 2015 May;183(5):487-96. doi: 10.1667/RR13959.1. Epub 2015 May 4. Review.

Supplemental Content

Support Center